Secondary Infertility — Preservation of Ovarian Tissue and Chemo-Radiotherapy
Citation(s)
Abir R, Fisch B, Jessel S, Felz C, Ben-Haroush A, Orvieto R Improving posttransplantation survival of human ovarian tissue by treating the host and graft. Fertil Steril. 2011 Mar 15;95(4):1205-10. doi: 10.1016/j.fertnstert.2010.07.1082.
Gook DA, Edgar DH Cryopreservation of the human female gamete: current and future issues. Hum Reprod. 1999 Dec;14(12):2938-40. Review.
Gook DA, McCully BA, Edgar DH, McBain JC Development of antral follicles in human cryopreserved ovarian tissue following xenografting. Hum Reprod. 2001 Mar;16(3):417-22.
Gosden R Cryopreservation: a cold look at technology for fertility preservation. Fertil Steril. 2011 Aug;96(2):264-8. doi: 10.1016/j.fertnstert.2011.06.029. Epub 2011 Jun 30. Review.
Gracia CR, Gracia JJ, Chen S Ethical dilemmas in oncofertility: an exploration of three clinical scenarios. Cancer Treat Res. 2010;156:195-208. doi: 10.1007/978-1-4419-6518-9_15.
Jeruss JS, Woodruff TK Preservation of fertility in patients with cancer. N Engl J Med. 2009 Feb 26;360(9):902-11. doi: 10.1056/NEJMra0801454. Review.
Kauffman HM, McBride MA, Delmonico FL First report of the United Network for Organ Sharing Transplant Tumor Registry: donors with a history of cancer. Transplantation. 2000 Dec 27;70(12):1747-51.
Meirow D, Lewis H, Nugent D, Epstein M Subclinical depletion of primordial follicular reserve in mice treated with cyclophosphamide: clinical importance and proposed accurate investigative tool. Hum Reprod. 1999 Jul;14(7):1903-7.
Moomjy M, Rosenwaks Z Ovarian tissue cryopreservation: the time is now. Transplantation or in vitro maturation: the time awaits. Fertil Steril. 1998 Jun;69(6):999-1000. Review.
Oktay K, Karlikaya G Ovarian function after transplantation of frozen, banked autologous ovarian tissue. N Engl J Med. 2000 Jun 22;342(25):1919.
Oktem O, Oktay K A novel ovarian xenografting model to characterize the impact of chemotherapy agents on human primordial follicle reserve. Cancer Res. 2007 Nov 1;67(21):10159-62.
Oktem O, Oktay K The role of extracellular matrix and activin-A in in vitro growth and survival of murine preantral follicles. Reprod Sci. 2007 May;14(4):358-66.
Qu J, Godin PA, Nisolle M, Donnez J Distribution and epidermal growth factor receptor expression of primordial follicles in human ovarian tissue before and after cryopreservation. Hum Reprod. 2000 Feb;15(2):302-10.
Rosen A, Rodriguez-Wallberg KA, Rosenzweig L Psychosocial distress in young cancer survivors. Semin Oncol Nurs. 2009 Nov;25(4):268-77. doi: 10.1016/j.soncn.2009.08.004. Review.
Shaw JM, Bowles J, Koopman P, Wood EC, Trounson AO Fresh and cryopreserved ovarian tissue samples from donors with lymphoma transmit the cancer to graft recipients. Hum Reprod. 1996 Aug;11(8):1668-73.
Silber S, Kagawa N, Kuwayama M, Gosden R Duration of fertility after fresh and frozen ovary transplantation. Fertil Steril. 2010 Nov;94(6):2191-6. doi: 10.1016/j.fertnstert.2009.12.073. Epub 2010 Feb 19.
Soleimani R, Heytens E, Oktay K Enhancement of neoangiogenesis and follicle survival by sphingosine-1-phosphate in human ovarian tissue xenotransplants. PLoS One. 2011 Apr 29;6(4):e19475. doi: 10.1371/journal.pone.0019475.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.